DLA Piper advised Iovance Biotherapeutics in the deal. Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) announced its definitive agreement with Clinigen Limited to acquire Proleukin® (aldesleukin), an interleukin-2...
Iovance Biotherapeutics’ $200 Million Acquisition of Proleukin
Skyward Specialty’s $134 Million Upsized Initial Public Offering
DLA Piper advised Skyward Specialty, while Latham & Watkins LLP represented the underwriters in the offering. Skyward Specialty Insurance Group, Inc., a specialty insurance company, delivering...